Previous 10 | Next 10 |
The obesity epidemic is still bursting at the seams. In fact, according to Medical News Today, the issue contributes to more than five million global deaths every year. In addition, a ccording to the World Health Organization, obesity has tripled since 1975. More than 1.9 billion adults...
Palm Beach, FL –November 17, 2021 – FinancialNewsMedia.com News Commentary – The uses of Ketamine for a variety of therapies are growing. An expanding number of clinics are offering ketamine infusion therapy for the treatment of mental health disorders and t...
Atai Life Sciences N.V. (ATAI) Q3 2021 Earnings Conference Call November 15, 2021, 08:30 AM ET Company Participants Chad Messer - VP, IR, Strategic Finance Florian Brand - CEO Srinivas Rao - Co-Founder & Chief Scientific Officer Greg Weaver - CFO Conference Call Participants Charles Dunca...
ATAI Life Sciences (NASDAQ:ATAI): Q3 GAAP EPS of -$0.21 beats by $0.02. Revenue of $0.27M Press Release Cash and cash equivalents totaled $430.3M as of September 30, 2021, compared to $97.2M as of December 31, 2020. For further details see: ATAI Life Sciences EPS beats by $0.02
-Positive topline results from COMP360’s Phase 2b study- -RL-007 Phase 2a topline data in cognitive impairment associated with schizophrenia expected end of Q4- -Continued progress across 11 therapeutic programs, including initiation of Perception’s Phase...
Mynaric (MYNA) soared more than 30% intraday Friday following a U.S. IPO for the German laser-communications firm, which enjoys backing from mega-investor Christian Angermayer, founder of legal-hallucinogens firm Atai Life Sciences (NASDAQ:ATAI). MYNA rose to as high as $22 per American Depos...
NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a conference call on Monday, November 15,...
NEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it will participate in the following upcoming investo...
Palm Beach, FL –November 4, 2021 – FinancialNewsMedia.com News Commentary – The pace of society’s change in attitude to the use of psychedelics has been amazing. It has gone from a “Born To Be Wild”, hippie counter-culture illegal drug...
It’s been more than 18 months since Fortune magazine declared “ psychedelic drugs may revolutionize mental healthcare. ” Fortune pointed out how “Silicon Valley legends” and “billionaire financiers” were the main drivers of a ...
News, Short Squeeze, Breakout and More Instantly...
ATAI Life Sciences N.V. Company Name:
ATAI Stock Symbol:
NASDAQ Market:
ATAI Life Sciences N.V. Website:
Psychedelics such as DMT, LSD and psilocybin have demonstrated promise in the treatment of affective symptoms of a range of disorders. These drugs work by inducing an altered state of consciousness , which includes intensified perceptions and emotions, which have been associated with therapeutic...